Clinical trial

An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors

NCT01618136

Study summary

ClinicalTrials.gov

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1, PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention E7449 alone Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention E7449 plus TMZ Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention E7449 plus carboplatin and paclitaxel Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2012-01-01

PhasePHASE1 / PHASE2

Conditions

Malignant Solid Tumourunresolved

Ovarian Cancerverified · MONDO: ovarian cancer

Triple Negative Breast Cancercandidate · MONDO: triple-negative breast carcinoma

Advanced Melanomaunresolved

B-cell Malignancy, Low-gradeunresolved

Interventions

E7449 aloneDRUG

E7449 plus TMZDRUG

E7449 plus carboplatin and paclitaxelDRUG

Sponsors & collaborators

Eisai Limitedlead sponsor

Mapped research locations

LondonUnited Kingdom1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01618136 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.